

INFORMAZIONI PERSONALI **Luca Richeldi**

Roma (Italia)

Sesso M | Data di Nascita 30/03/1963 | Nazionalità Italiana

POSIZIONE RICOPERTA
(UNIVERSITA' – RUOLO)

Luca Richeldi ricopre la carica di **Professore delle Malattie dell'Apparato Respiratorio** presso la Fondazione Policlinico A. Gemelli, Università Cattolica del Sacro Cuore (Roma) - Gennaio 2017

Direttore dell' Unità Operativa Complessa di Pneumologia - Polo delle Scienze Cardiovascolari e Toraciche presso la Fondazione Policlinico A. Gemelli, Università Cattolica del Sacro Cuore (Roma) - Gennaio 2017

ESPERIENZA
PROFESSIONALE

Dal 2013 al 2016	Direttore del Centro per le Malattie Rare del Polmone e Professore Associato di malattie dell'apparato respiratorio presso l'Università di Southampton (Inghilterra) Consulente Onorario presso il "General Hospital MHS Trust" di Southampton (Inghilterra).
Dal 2012 al 2013	Vice Direttore della Facoltà di Medicina.
Dal 2005 al 2013	Professore Associato di Medicina Respiratoria presso l'Università di Modena e Reggio Emilia (Italia).
Dal 2005 al 2008	Direttore della Scuola di Specializzazione di Medicina Respiratoria presso l'Università di Modena (Italia).
Dal 2006 al 2013	Consulente Onorario di malattie dell'Apparato Respiratorio presso l'AOU Policlinico di Modena (Italia)
Dal 2007 al 2013	Direttore del Centro per le Malattia Rare del Polmone presso l'AOU Policlinico di Modena (Italia).
Da 1997 al 2005	Consulente in Medicina Respiratoria presso il Policlinico di Modena (Italia).
Dal 1996 al 1997	Professore a contratto presso la Scuola di Specializzazione in Malattie dell'Apparato Respiratorio presso l'Università di Roma "La Sapienza" (Italia).
Dal 1993 al 1996	Dottorato di Ricerca in Fisiopatologia Cardiorespiratoria presso l'Università di Roma "La Sapienza" (Italia).
Dal 1990 al 1993	Dottorato di Ricerca presso l'Università di Roma "La Sapienza" (Italia).
Anno 1988	Laurea in Medicina presso l'Università di Modena (Italia) e nello stesso anno consegue

l'abilitazione alla professione di Medico Chirurgo.

ULTERIORI INFORMAZIONI

Responsabile della stesura delle **linee guida Internazionali sulla Diagnosi e Terapia della Fibrosi Polmonare Idiopatica** (*Idiopathic Pulmonary Fibrosis*) e sulla classificazione della polmonite interstiziale idiopatica – linee guida e raccomandazioni approvate dalle più prestigiose società internazionali in campo Respiratorio tra cui “*American Thoracic Society*” e la “*European Respiratory Society*”.

MEMBRO DEI COMITATI INTERNAZIONALI

- American Thoracic Society, “Microbiology, Tuberculosis and Pulmonary Infections”: membro della Conference Program Committee (2006-2009), del Planning Committee (2009-2011) e del Nominating Committee (2012-2013)
- Centers for Disease Control and Prevention, USA, Updated Guidelines for Using Interferon Gamma Release Assays to Detect Mycobacterium tuberculosis Infection: membro del comitato scientifico (2009-2010).
- American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Respiratory Society, Evidence-based Guidelines for Management of Idiopathic Pulmonary Fibrosis: membro del comitato scientifico (2007-2011)
- American Thoracic Society/Centers for Disease Control and Prevention/Infectious Disease Society of America, Diagnostic Standards and Classification of Tuberculosis in Adults and Children: membro del comitato scientifico (dal 2008 ad oggi)
- American Thoracic Society/European Respiratory Society, International Multidisciplinary Classification of Idiopathic Interstitial Pneumonias: membro del Comitato scientifico (dal 2009 ad oggi)
- American Thoracic Society/European Respiratory Society, International Working Group on Undifferentiated forms of CTD-ILD: membro del Comitato scientifico (dal 2012 ad oggi)
- American Thoracic Society, “Clinical problems assembly”: membro della Conference Program Committee (2014-2016)

MEMBRO DELLE SOCIETA' INTERNAZIONALI SCIENTIFICHE

- Fleischner Society: membro attivo
- Pulmonary Fibrosis Foundation: Presidente del Gruppo Internazionale
- The Association of Physicians of Great Britain and Ireland: membro
- The Cochrane Collaboration: membro (Gruppo “Airways”)
- American Thoracic Society: membro
- European Respiratory Society: membro
- Italian Respiratory Society: membro e segretario del gruppo “Infections and Tuberculosis”

ATTIVITA' EDITORIALE

Luca Richeldi ha contribuito alla stesura di vari capitoli medico-scientifici ed è autore di circa 300 articoli scientifici pubblicati nei giornali internazionali tra cui:

- The Lancet Respiratory Medicine:
- European Respiratory Journal
- American Journal of Respiratory and Critical Care Medicine
- BMC Medicine
- Sarcoidosis, Vasculitis and Diffuse Lung Diseases
- Pulmonary Pharmacology & Therapeutics
- The Clinical Respiratory Journal

PUBBLICAZIONI DI RICERCA SCIENTIFICA (Original articles)

1. Capelli A, Capelli O, Azzolini L, **Richeldi L**, Prandi E, Velluti G. Activities of human alveolar macrophages (HAMs). Note 1: Observations on phagocytosis and bacterial killing in the presence of miconazole. *Chemioterapia*. 1988; 7(2): 89-95.
2. Velluti G, Capelli O, **Richeldi L**, Prandi E, Lega M, Rovatti E, Covi M. Functional activities of human alveolar macrophages. *Eur Respir J*. 1990; 3(3): 361-2.
3. Amicosante M, Paone G, Ameglio F, Bianchi EL, Piccolella E, **Richeldi L**, Bisetti A, Luisetti M, Saltini C. Antibody repertoire against the A60 antigen complex during the course of pulmonary tuberculosis. *Eur Respir J*. 1993; 6(6): 816-22.
4. **Richeldi L**, Sorrentino R, Saltini C. HLA-DPB1 glutamate 69: a genetic marker of beryllium disease. *Science*. 1993; 262(5131): 242-4.
5. Amicosante M, **Richeldi L**, Trenti G, Paone G, Campa M, Bisetti A, Saltini C. Inactivation of polymerase inhibitors for Mycobacterium tuberculosis DNA amplification in sputum by using capture resin. *J Clin Microbiol*. 1995; 33(3): 629-30.
6. Amicosante M, **Richeldi L**, Monno L, Cuboni A, Tartoni PL, Angarano G, Orefici G, Saltini C. Serological markers predicting tuberculosis in human immunodeficiency virus-infected patients. *Int J Tuberc Lung Dis*. 1997; 1(5): 435-40.
7. **Richeldi L**, Kreiss K, Mroz MM, Zhen B, Tartoni P, Saltini C. Interaction of genetic and exposure factors in the prevalence of berylliosis. *Am J Ind Med*. 1997; 32(4): 337-40.
8. Voorter C, **Richeldi L**, Gervais T, van den Berg-Loonen E. Identification of two new DPB1 alleles, DPB1*7701 and *7801, by sequence-based typing. *Tissue Antigens*. 1998; 52(2): 190-2.
9. Agostini C, Albera C, Bariffi F, De Palma M, Harari S, Lusuardi M, Pesci A, Poletti V, **Richeldi L**, Rizzato G, Rossi A, Schiavina M, Semenzato G, Tinelli C. First report of the Italian register for diffuse infiltrative lung disorders (RIPID). *Monaldi Arch Chest Dis*. 2001; 56(4): 364-8.
10. Saltini C, **Richeldi L**, Losi M, Amicosante M, Voorter C, van den Berg-Loonen E, Dweik RA, Wiedemann HP, Deubner DC, Tinelli C. Major histocompatibility locus genetic markers of beryllium sensitization and disease. *Eur Respir J*. 2001; 18(4): 677-84.
11. **Richeldi L**, Covi M, Ferrara G, Franco F, Vailati P, Meschiari E, Fabbri LM, Velluti G. Clinical use of Levofloxacin in the long-term treatment of drug resistant tuberculosis. *Monaldi Arch Chest Dis*. 2002; 57(1): 39-43.
12. **Richeldi L**, Ferrara G, Fabbri LM, Gibson PG. Macrolides for chronic asthma. *Cochrane Database Syst Rev*. 2002; (1): CD002997.
13. Davies HR, **Richeldi L**, Walters EH. Immunomodulatory agents for idiopathic pulmonary fibrosis. *Cochrane Database Syst Rev*. 2003; (3): CD003134.
14. Nasi M, Borghi V, Pinti M, Bellodi C, Lugli E, Maffei S, Troiano L, **Richeldi L**, Mussini C, Esposito R, Cossarizza A. MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients. *AIDS*. 2003; 17(11): 1696-8.
15. **Richeldi L**, Davies HR, Ferrara G, Franco F. Corticosteroids for idiopathic pulmonary fibrosis. *Cochrane Database Syst Rev*. 2003; (3): CD002880.
16. **Richeldi L**, Ewer K, Losi M, Bergamini BM, Roversi P, Deeks J, Fabbri LM, Lalvani A. T cell-based tracking of multidrug resistant tuberculosis infection after brief exposure. *Am J Respir Crit Care Med*. 2004; 170(3): 288-95.
17. **Richeldi L**, Ewer K, Losi M, Hansell DM, Roversi P, Fabbri LM, Lalvani A. Early diagnosis of subclinical multidrug-resistant tuberculosis. *Ann Intern Med*. 2004; 140(9): 709-13.
18. **Richeldi L**, Mariani M, Losi M, Maselli F, Corbetta L, Buonsanti C, Colonna M, Sinigaglia F, Panina-Bordignon P, Fabbri LM. Triggering receptor expressed on myeloid cells: role in the diagnosis of lung infections. *Eur Respir J*. 2004; 24(2): 247-50.

19. Ferrara G, Losi M, Meacci M, Meccugni B, Piro R, Roversi P, Bergamini BM, D'Amico R, Marchegiano P, Rumpianesi F, Fabbri LM, **Richeldi L**. Routine hospital use of a new commercial whole blood interferon-gamma assay for the diagnosis of tuberculosis infection. *Am J Respir Crit Care Med*. 2005; 172(5): 631-5.
20. Ferrara G, **Richeldi L**, Bugiani M, Cirillo D, Besozzi G, Nutini S, Casali L, Fiorentini F, Codecasa LR, Migliori GB. Management of multidrug-resistant tuberculosis in Italy. *Int J Tuberc Lung Dis*. 2005; 9(5): 507-13.
21. **Richeldi L**, De Guglielmo M, Fabbri LM, Giovanardi D, Marchetti F, Larosa M, Solfrini V, Altini M. Management of CAP using a validated risk score. *Thorax*. 2005; 60(2): 172-3.
22. **Richeldi L**, Ferrara G, Fabbri LM, Lasserson TJ, Gibson PG. Macrolides for chronic asthma. *Cochrane Database Syst Rev*. 2005; (4): CD002997.
23. Tinelli C, De Silvestri A, **Richeldi L**, Oggionni T. The Italian register for diffuse infiltrative lung disorders (RIPID): a four-year report. *Sarcoidosis Vasc Diffuse Lung Dis*. 2005; 22 Suppl 1: S4-8.
24. Ferrara G, Losi M, D'Amico R, Roversi P, Piro R, Meacci M, Meccugni B, Dori IM, Andreani A, Bergamini BM, Mussini C, Rumpianesi F, Fabbri LM, **Richeldi L**. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with *Mycobacterium tuberculosis*: a prospective study. *Lancet* [Fast Track]. 2006; 367(9519): 1328-34.
25. **Richeldi L**, Ewer K, Losi M, Roversi P, Fabbri LM, Lalvani A. Repeated tuberculin testing does not induce false positive ELISPOT results. *Thorax*. 2006; 61(2): 180.
26. **Richeldi L**, Luppi M, Losi M, Luppi F, Potenza L, Roversi P, Cerri S, Millington KA, Ewer K, Fabbri LM, Torelli G, Lalvani A. Diagnosis of occult tuberculosis in hematological malignancy by enumeration of antigen-specific T cells. *Leukemia*. 2006; 20(2): 379-81.
27. Ciaschetti A, Franchi A, **Richeldi L**, Rumpianesi F, Meacci M, Valente A, Franco G. [Screening of latent tuberculosis infection in health care workers by QuantiFERON-TB and tuberculin skin test]. *G Ital Med Lav Ergon*. 2007; 29(3 Suppl): 406-7.
28. Davies G, Cerri S, **Richeldi L**. Rifabutin for treating pulmonary tuberculosis. *Cochrane Database Syst Rev*. 2007; (4): CD005159.
29. Franchi A, **Richeldi L**, Parrinello G, Franco G. Room size is the major determinant for tuberculin conversion in health care workers exposed to a multidrug-resistant tuberculosis patient. *Int Arch Occup Environ Health*. 2007; 80(6): 533-8.
30. Gooding S, Chowdhury O, Hinks T, **Richeldi L**, Losi M, Ewer K, Millington K, Gunatheesan R, Cerri S, McNally J, Lalvani A. Impact of a T cell-based blood test for tuberculosis infection on clinical decision-making in routine practice. *J Infect*. 2007; 54(3): e169-74.
31. Losi M, Bossink A, Codecasa L, Jafari C, Ernst M, Thijsen S, Cirillo D, Ferrarese M, Greinert U, Fabbri LM, **Richeldi L**, Lange C. Use of a T-cell interferon-gamma release assay for the diagnosis of tuberculous pleurisy. *Eur Respir J*. 2007; 30(6): 1173-9.
32. **Richeldi L**, Ewer K, Losi M, Bergamini BM, Millington K, Fabbri LM, Lalvani A. T-cell-based diagnosis of neonatal multidrug-resistant latent tuberculosis infection. *Pediatrics*. 2007; 119(1): e1-5.
33. Ferrara G, Bleck B, **Richeldi L**, Reibman J, Fabbri LM, Rom WN, Condos R. *Mycobacterium tuberculosis* induces CCL18 expression in human macrophages. *Scand J Immunol*. 2008; 68(6): 668-74.
34. **Richeldi L**, Bergamini BM, Vaienti F. Prior tuberculin skin testing does not boost QuantiFERON-TB results in paediatric contacts. *Eur Respir J*. 2008; 32(2): 524-5.
35. Rossi G, Andreani A, Morandi P, Marchioni A, Corradini P, Cappiello G, Bortolotti M, Qosja A, Manzini C, Ferri C, **Richeldi L**, Cavazza A. Eosinophilic globules in bronchoalveolar lavage fluid of patients with systemic sclerosis-related interstitial lung disease: a diagnostically useful, previously unreported finding in a retrospective and prospective study, including differential diagnosis with other idiopathic and secondary interstitial lung diseases. *Am J Clin Pathol*. 2008; 130(6): 927-33.
36. Bergamini BM, Losi M, Vaienti F, D'Amico R, Meccugni B, Meacci M, De Giovanni D, Rumpianesi F, Fabbri LM, Balli F, **Richeldi L**. Performance of commercial blood tests for the diagnosis of latent tuberculosis infection in children and adolescents. *Pediatrics*. 2009; 123(3): e419-24.

37. Ferrara G, Losi M, D'Amico R, Cagarelli R, Pezzi AM, Meacci M, Meccugni B, Marchetti Dori I, Rumpianesi F, Roversi P, Casali L, Fabbri LM, **Richeldi L**. Interferon-gamma-release assays detect recent tuberculosis re-infection in elderly contacts. *Int J Immunopathol Pharmacol*. 2009; 22(3): 669-77.
38. Jafari C, Thijssen S, Sotgiu G, Goletti D, Dominguez Benitez JA, Losi M, Eberhardt R, Kirsten D, Kalsdorf B, Bossink A, Latorre I, Migliori GB, Strassburg A, Winteroll S, Greinert U, **Richeldi L**, Ernst M, Lange C. Bronchoalveolar lavage enzyme-linked immunospot for a rapid diagnosis of tuberculosis: a Tuberculosis Network European Trialsgroup study. *Am J Respir Crit Care Med*. 2009; 180(7): 666-73.
39. Luppi F, Losi M, D'Amico R, Fabbri LM, **Richeldi L**. Endogenous blood maximal interferon-gamma production may predict response to interferon-gamma 1beta treatment in patients with idiopathic pulmonary fibrosis. *Sarcoidosis Vasc Diffuse Lung Dis*. 2009; 26(1): 64-8.
40. **Richeldi L**, Losi M, D'Amico R, Luppi M, Ferrari A, Mussini C, Codeluppi M, Cocchi S, Prati F, Paci V, Meacci M, Meccugni B, Rumpianesi F, Roversi P, Cerri S, Luppi F, Ferrara G, Latorre I, Gerunda GE, Torelli G, Esposito R, Fabbri LM. Performance of tests for latent tuberculosis in different groups of immunocompromised patients. *Chest*. 2009; 136(1): 198-204.
41. Colaci M, Sebastiani M, Giuggioli D, Manfredi A, Spagnolo P, Luppi F, **Richeldi L**, Ferri C. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma alveolitis. *Scand J Rheumatol*. 2010; 39(2): 155-9.
42. Spagnolo P, Del Giovane C, Luppi F, Cerri S, Balduzzi S, Walters EH, D'Amico R, **Richeldi L**. Non-steroid agents for idiopathic pulmonary fibrosis. *Cochrane Database Syst Rev*. 2010; (9): CD003134.
43. Losi M, Bergamini BM, Venturelli C, Del Giovane C, Sighinolfi G, Rumpianesi F, **Richeldi L**. Tuberculosis infection in foreign-born children: a screening survey based on skin and blood testing. *Int J Tuberc Lung Dis*. 2011; 15(9): 1182-4, i.
44. Losi M, Bocchino M, Matarese A, Bellofiore B, Roversi P, Rumpianesi F, Alma MG, Chiaradonna P, Del Giovane C, Altieri AM, **Richeldi L**, Sanduzzi A. Role of the QuantiFERON-TB test in ruling out pleural tuberculosis: a multi-centre study. *Int J Immunopathol Pharmacol*. 2011; 24(1): 159-65.
45. Luppi F, Covi M, Velluti G, Spagnolo P, Fabbri LM, **Richeldi L**. Co-trimoxazole effect on human alveolar macrophages of AIDS patients. *J Biol Regul Homeost Agents*. 2011; 25(3): 461-4.
46. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE, Jr., Kondoh Y, Myers J, Muller NL, Nicholson AG, **Richeldi L**, Selman M, Dudden RF, Griss BS, Protzko SL, Schönemann HJ. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. *Am J Respir Crit Care Med*. 2011; 183(6): 788-824.
47. **Richeldi L**, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, Brown KK, Flaherty KR, Noble PW, Raghu G, Brun M, Gupta A, Juhel N, Klüglich M, du Bois RM. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. *N Engl J Med*. 2011; 365(12): 1079-87.
48. Ruhwald M, Dominguez J, Latorre I, Losi M, **Richeldi L**, Pasticci MB, Mazzolla R, Goletti D, Butera O, Bruchfeld J, Gaines H, Gerogianni I, Tuuminen T, Ferrara G, Eugen-Olsen J, Ravn P. A multicentre evaluation of the accuracy and performance of IP-10 for the diagnosis of infection with M. tuberculosis. *Tuberculosis (Edinb)*. 2011; 91(3): 260-7.
49. **Richeldi L**, Ryerson CJ, Lee JS, Wolters PJ, Koth LL, Ley B, Elicker BM, Jones KD, King TE, Jr., Ryu JH, Collard HR. Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. *Thorax*. 2012; 67(5): 407-11.
50. Ryerson CJ, Urbania TH, **Richeldi L**, Mooney JJ, Lee JS, Jones KD, Elicker BM, Koth LL, King TE, Jr., Wolters PJ, Collard HR. Prevalence and prognosis of unclassifiable interstitial lung disease. *Eur Respir J*. 2013; 42(3): 750-7.
51. Lee JS, Kim EJ, Lynch KL, Elicker B, Ryerson CJ, Katsumoto TR, Shum AK, Wolters PJ, Cerri S, **Richeldi L**, Jones KD, King TE, Jr., Collard HR. Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis. *Respir Med*. 2013; 107(2): 249-55.
52. Raghu G, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, Martinez FJ, Nathan SD, Wells AU, Collard HR, Costabel U, **Richeldi L**, de Andrade J, Khalil N, Morrison LD, Lederer DJ, Shao L, Li X, Pedersen PS,

- Montgomery AB, Chien JW, O'Riordan TG. Treatment of idiopathic pulmonary fibrosis with ambrisentan, a selective antagonist of the endothelin a receptor: a randomized trial. *Ann Intern Med.* 2013; 158(9): 641-9.
53. Collard HR, Yow E, **Richeldi L**, Anstrom KJ, Glazer C; IPFnet investigators. Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. *Respir Res.* 2013; 14: 73.
54. Travis WD, Costabel U, Hansell DM, King, Jr. TE, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU, Behr J, Bouros D, Brown KK, Colby TV, Collard HR, Robalo Cordeiro C, Cottin V, Crestani B, Drent M, Dudden RF, Egan J, Flaherty K, Hogaboam C, Inoue Y, Johkoh T, Kim DS, Kitaichi M, Loyd J, Martinez FJ, Myers J, Protzko S, Raghu G, **Richeldi L**, Sverzellati N, Swigris J, Valeyre D. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. *Am J Respir Crit Care Med.* 2013; 188(6): 733-48.
55. Saketkoo LA, Mittoo S, Huscher D, Khanna D, Dellaripa PF, Distler O, Flaherty KR, Frankel S, Oddis CV, Denton CP, Fischer A, Kowal-Bielecka OM, Lesage D, Merkel PA, Phillips K, Pittrow D, Swigris J, Antoniou K, Baughman RP, Castellino FV, Christmann RB, Christopher-Stine L, Collard HR, Cottin V, Danoff S, Highland KB, Hummers L, Shah AA, Kim DS, Lynch DA, Miller FW, Proudman SM, **Richeldi L**, Ryu JH, Sandorfi N, Sarver C, Wells AU, Strand V, Matteson EL, Brown KK, Seibold JR. Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. *Thorax.* 2014; 69: 428-36.
56. Saketkoo LA, Mittoo S, Frankel S, LeSage D, Sarver C, Phillips K, Strand V, Matteson EL; OMERACT Connective Tissue Disease–Interstitial Lung Diseases Working Group; OMERACT Connective Tissue Disease–Interstitial Lung Diseases Working Group. Reconciling healthcare professional and patient perspectives in the development of disease activity and response criteria in connective tissue disease-related interstitial lung diseases. *J Rheumatol.* 2014; 41: 792-8.
57. Jaffar J, Unger S, Corte TJ, Keller M, Wolters PJ, **Richeldi L**, Cerri S, Prêlle CM, Hansbro PM, Argraves WS, Oliver RA, Oliver BG, Black JL, Burgess JK. Fibulin-1 predicts disease progression in patients with idiopathic pulmonary fibrosis. *Chest.* 2014 May 15. doi: 10.1378/chest.13-2688. [Epub ahead of print]
58. **Richeldi L**, Cottin V, Flaherty KR, Kolb M, Inoue Y, Raghu G, Taniguchi H, Hansell DM, Nicholson AG, Le Maulf F, Stowasser S, Collard HR. Design of the INPULSIS™ trials: Two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis. *Respir Med.* 2014; 108: 1023-30.
59. **Richeldi L**, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR; INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. *N Engl J Med.* 2014; 370: 2071-82.
60. Banville N, Burgess JK, Jaffar J, Tjin G, **Richeldi L**, Cerri S, Persiani E, Black JL, Oliver BG. A quantitative proteomic approach to identify significantly altered protein networks in the serum of patients with lymphangioleiomyomatosis (LAM). *PLoS One.* 2014; 9: e105365.
61. Ley B, Elicker BM, Hartman TE, Ryerson CJ, Vittinghoff E, Ryu JH, Lee JS, Jones KD, **Richeldi L**, King TE Jr, Collard HR. Idiopathic Pulmonary Fibrosis: CT and Risk of Death. *Radiology.* 2014; 273: 570-9.
62. Udwadia ZF, Mullerpattan JB, Balakrishnan C, **Richeldi L**. Improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis. *Lung India.* 2015 Jan-Feb; 32(1): 50-2.
63. Sgalla G, Cerri S, Ferrari R, Ricchieri MP, Poletti S, Ori M, Garuti M, Montanari G, Luppi F, Petropulacos K, **Richeldi L**. Mindfulness-based stress reduction in patients with interstitial lung diseases: a pilot, single-centre observational study on safety and efficacy. *BMJ Open Respir Res.* 2015; 2: e000065. doi: 10.1136/bmjresp-2014-000065.
64. Hansell DM, Goldin JG, King TE Jr, Lynch DA, **Richeldi L**, Wells AU. CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a Position Paper from the Fleischner society. *Lancet Respir Med.* 2015; 3: 483-496.
65. Fischer A, Antoniou KM, Brown KK, Cadranet J, Corte TJ, du Bois RM, Lee JS, Leslie KO, Lynch DA, Matteson EL, Mosca M, Noth I, **Richeldi L**, Streck ME, Swigris JJ, Wells AU, West SG, Collard HR, Cottin V; "ERS/ATS Task Force on Undifferentiated Forms of CTD-ILD". An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. *Eur Respir J.* 2015; 46: 976-87.

66. Raghu G, Rochweg B, Zhang Y, Garcia CA, Azuma A, Behr J, Brozek JL, Collard HR, Cunningham W, Homma S, Johkoh T, Martinez FJ, Myers J, Protzko SL, **Richeldi L**, Rind D, Selman M, Theodore A, Wells AU, Hoogsteden H, Schönemann HJ; ATS, ERS, JRS, and ALAT. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. *Am J Respir Crit Care Med*. 2015 Jul 15;192(2):e3-e19. doi: 10.1164/rccm.201506-1063ST.
67. Thabut G, Crestani B, Porcher R, **Richeldi L**. Missing data in IPF trials: do not let methodological issues undermine a major therapeutic breakthrough. *Eur Respir J*. 2015; 46: 607-14.
68. Costabel U, Inoue Y, **Richeldi L**, Collard HR, Tschöepe I, Stowasser S, Azuma A. Efficacy of nintedanib in idiopathic pulmonary fibrosis across pre-specified subgroups in INPULSIS. *Am J Respir Crit Care Med*. 2015 Sep 22. [Epub ahead of print] PubMed PMID: 26393389.
69. Corte T, Bonella F, Crestani B, Demedts MG, **Richeldi L**, Coeck C, Pelling K, Quaresma M, Lasky JA. Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. *Respir Res*. 2015 Sep 24;16(1):116. doi: 10.1186/s12931-015-0276-5.
70. De Biasi S, Cerri S, Bianchini E, Gibellini L, Persiani E, Montanari G, Luppi F, Carbonelli CM, Zucchi L, Bocchino M, Zamparelli AS, Vancheri C, Sgalla G, **Richeldi L**, Cossarizza A. Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments. *BMC Med*. 2015; 13: 277.
71. Costabel U, Inoue Y, **Richeldi L**, Collard HR, Tschöepe I, Stowasser S, Azuma A. Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS. *Am J Respir Crit Care Med*. 2016; 193: 178-85.
72. Rochweg B, Neupane B, Zhang Y, Garcia CC, Raghu G, **Richeldi L**, Brozek J, Beyene J, Schönemann H. Treatment of idiopathic pulmonary fibrosis: a network meta-analysis. *BMC Med*. 2016; 14: 18.
73. **Richeldi L**, Cottin V, du Bois RM, Selman M, Kimura T, Bailes Z, Schlenker-Herceg R, Stowasser S, Brown KK. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS trials. *Resp Med*. 2016; 113: 74-9.
74. Jones MG, Fabre A, Schneider P, Cinetto F, Sgalla G, Mavrogordato M, Jogai S, Alzetani A, Marshall BG, O'Reilly KMA, Warner JA, Lackie PM, Davies DE, Hansell DM, Nicholson AG, Sinclair I, Brown KK, **Richeldi L**. Three-dimensional characterization of fibroblast foci in idiopathic pulmonary fibrosis. *JCI Insight*. 2016; 1: e86375.
75. Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, Lee JS, Maher TM, Wells AU, Antoniou KM, Behr J, Brown KK, Cottin V, Flaherty KR, Fukuoka J, Hansell DM, Johkoh T, Kaminski N, Kim DS, Kolb M, Lynch DA, Myers JL, Raghu G, **Richeldi L**, Taniguchi H, Martinez FJ. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. *Am J Respir Crit Care Med*. 2016; 194: 265-75.
76. Kolb M, **Richeldi L**, Behr J, Maher TM, Tang W, Stowasser S, Hallmann C, du Bois RM. Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. *Thorax*. 2016 Sep 26. pii: thoraxjnl-2016-208710. doi: 10.1136/thoraxjnl-2016-208710.
77. Raghu G, Wells AU, Nicholson AG, **Richeldi L**, Flaherty KR, Le Maulf F, Stowasser S, Schlenker-Herceg R, Hansell DM. Effect of nintedanib in subgroups of idiopathic pulmonary fibrosis by diagnostic criteria. *Am J Respir Crit Care Med*. 2017; 195: 78-85.
78. Lewinsohn DM, Leonard MK, LoBue PA, Cohn DL, Daley CL, Desmond E, Keane J, Lewinsohn DA, Loeffler AM, Mazurek GH, O'Brien RJ, Pai M, **Richeldi L**, Salfinger M, Shinnick TM, Sterling TR, Warshauer DM, Woods GL. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. *Clin Infect Dis*. 2017; 64: 111-115.

REVISIONE ED EDITORIALI

1. Saltini C, Amicosante M, Li Bianchi E, Paone G, **Richeldi L**, Guerritore D, Pallotta G, Bisetti A. [Mycobacterium tuberculosis. From the gene to the diagnosis]. *Recenti Prog Med*. 1992; 83(1): 38-45.
2. Saltini C, Sorrentino R, **Richeldi L**, Luisetti M, Bisetti A. Role of the HLA-DP gene in susceptibility to lung granulomas. *Sarcoidosis*. 1993; 10(2): 171-2.
3. **Richeldi L**, Barnini S, Saltini C. Molecular diagnosis of tuberculosis. *Eur Respir J Suppl*. 1995; 20: 689s-700s.

4. Saltini C, **Richeldi L**. A genetic marker for chronic beryllium disease. *Med Lav*. 1995; 86(3): 226-8.
5. Saltini C, Amicosante M, Franchi A, Lombardi G, **Richeldi L**. Immunogenetic basis of environmental lung disease: lessons from the berylliosis model. *Eur Respir J*. 1998; 12(6): 1463-75.
6. Maestrelli P, **Richeldi L**, Moretti M, Fabbri LM. Analysis of sputum in COPD. *Thorax*. 2001; 56(6): 420-2.
7. Davies HR, **Richeldi L**. Idiopathic pulmonary fibrosis: current and future treatment options. *Am J Respir Med*. 2002; 1(3): 211-24.
8. Luppi F, Cerri S, Beghe B, Fabbri LM, **Richeldi L**. Corticosteroid and immunomodulatory agents in idiopathic pulmonary fibrosis. *Respir Med*. 2004; 98(11): 1035-44.
9. Ferrara G, Losi M, Franco F, Corbetta L, Fabbri LM, **Richeldi L**. Macrolides in the treatment of asthma and cystic fibrosis. *Respir Med*. 2005; 99(1): 1-10.
10. Luppi F, Cerri S, **Richeldi L**. Steroid and/or other immunosuppressive therapies in idiopathic interstitial pneumonias: have they still a role? *Sarcoidosis Vasc Diffuse Lung Dis*. 2005; 22 Suppl 1: S74-84.
11. **Richeldi L**. Chronic beryllium disease: a model for pulmonary sarcoidosis? *Acta Biomed*. 2005; 76 Suppl 2: 11-4.
12. Ferrara G, Losi M, Roversi P, Fabbri LM, **Richeldi L**. [New tools for a better diagnosis of latent tuberculosis infection]. *Recenti Prog Med*. 2006; 97(3): 123-8.
13. **Richeldi L**. An update on the diagnosis of tuberculosis infection. *Am J Respir Crit Care Med*. 2006; 174(7): 736-42.
14. **Richeldi L**, Abraham E. Identifying patients with idiopathic pulmonary fibrosis: quality or quantity? *Am J Respir Crit Care Med*. 2007; 175(10): 976-7.
15. **Richeldi L**, Losi M, Cerri S, Casali L, Fabbri LM, Ferrara G. Using ELISpot technology to improve the diagnosis of tuberculosis infection: from the bench to the T-SPOT.TB assay. *Expert Rev Respir Med*. 2008; 2(2): 253-60.
16. Spagnolo P, **Richeldi L**, du Bois RM. Environmental triggers and susceptibility factors in idiopathic granulomatous diseases. *Semin Respir Crit Care Med*. 2008; 29(6): 610-9.
17. Ferrara G, Losi M, Fabbri LM, Migliori GB, **Richeldi L**, Casali L. Exploring the immune response against Mycobacterium tuberculosis for a better diagnosis of the infection. *Arch Immunol Ther Exp (Warsz)*. 2009; 57(6): 425-33.
18. **Richeldi L**. Diagnosing latent tuberculosis infection: guess who's coming to dinner? *Am J Respir Crit Care Med*. 2009; 180(1): 1-2.
19. Luppi F, Beghé B, **Richeldi L**. Acute exacerbations of chronic obstructive pulmonary disease: are antibiotics needed? *Am J Respir Crit Care Med*. 2010; 181(2): 102-3.
20. **Richeldi L**. [Role of in vitro tests in the diagnosis of latent tubercular infections]. *G Ital Med Lav Ergon*. 2010; 32(3): 269-72.
21. Rossi G, Tironi A, Dore R, Nannini N, Mengoli MC, Bertolani M, **Richeldi L**. Pulmonary eosinophilic infiltrates. *Pathologica*. 2010; 102(6): 537-46.
22. Spagnolo P, Zeuzem S, **Richeldi L**, du Bois RM. The complex interrelationships between chronic lung and liver disease: a review. *J Viral Hepat*. 2010; 17(6): 381-90.
23. Kolb MR, **Richeldi L**. Viruses and acute exacerbations of idiopathic pulmonary fibrosis: rest in peace? *Am J Respir Crit Care Med*. 2011; 183(12): 1583-4.
24. Noble PW, **Richeldi L**, Kaminski N. End of an ERA: lessons from negative clinical trials in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med*. 2011; 184(1): 4-5.
25. **Richeldi L**, du Bois RM. Pirfenidone in idiopathic pulmonary fibrosis: the CAPACITY program. *Expert Rev Respir Med*. 2011; 5(4): 473-81.
26. **Richeldi L**, Yasothan U, Kirkpatrick P. Pirfenidone. *Nat Rev Drug Discov*. 2011; 10(7): 489-90.
27. Selman M, Pardo A, **Richeldi L**, Cerri S. Emerging drugs for idiopathic pulmonary fibrosis. *Expert Opin Emerg Drugs*. 2011; 16(2): 341-62.

28. Blasi F, Bocchino M, Di Marco F, **Richeldi L**, Aliberti S. The role of biomarkers in low respiratory tract infections. *Eur J Intern Med.* 2012; 23(5): 429-35.
29. Cerri S, Spagnolo P, Luppi F, **Richeldi L**. Management of idiopathic pulmonary fibrosis. *Clin Chest Med.* 2012; 33(1): 85-94.
30. du Bois RM, Nathan SD, **Richeldi L**, Schwarz MI, Noble PW. Idiopathic pulmonary fibrosis: lung function is a clinically meaningful endpoint for phase III trials. *Am J Respir Crit Care Med.* 2012; 186(8): 712-5.
31. Luppi F, Spagnolo P, Cerri S, **Richeldi L**. The big clinical trials in idiopathic pulmonary fibrosis. *Curr Opin Pulm Med.* 2012; 18(5): 428-32.
32. **Richeldi L**. Treating idiopathic pulmonary fibrosis: current opportunities and future challenges. *Clin Respir J.* 2012; 6(3): 129-30.
33. **Richeldi L**. Assessing the treatment effect from multiple trials in idiopathic pulmonary fibrosis. *Eur Respir Rev.* 2012; 21(124): 147-51.
34. Spagnolo P, Luppi F, Cerri S, **Richeldi L**. Genetic testing in diffuse parenchymal lung disease. *Orphanet J Rare Dis.* 2012; 7: 79.
35. Spagnolo P, Luppi F, Roversi P, Cerri S, Fabbri LM, **Richeldi L**. Sarcoidosis: challenging diagnostic aspects of an old disease. *Am J Med.* 2012; 125(2): 118-25.
36. Spagnolo P, Tonelli R, Cocconcelli E, Stefani A, **Richeldi L**. Idiopathic pulmonary fibrosis: diagnostic pitfalls and therapeutic challenges. *Multidiscip Respir Med.* 2012; 7(1): 42.
37. Wells AU, Behr J, Costabel U, Cottin V, Poletti V, **Richeldi L**. Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good. *Thorax.* 2012; 67(11): 938-40.
38. Colaci M, Giuggioli D, Sebastiani M, Manfredi A, Vacchi C, Spagnolo P, Cerri S, Luppi F, **Richeldi L**, Ferri C. Lung cancer in scleroderma: Results from an Italian rheumatologic center and review of the literature. *Autoimmun Rev.* 2013; 12(3): 374-9.
39. **Richeldi L**, Collard HR, du Bois RM, Jenkins G, Kolb M, Maher TM, Raghu G, Vancheri C, Laurent GJ. Mapping the future for pulmonary fibrosis: report from the 17th International Colloquium on Lung and Airway Fibrosis. *Eur Respir J.* 2013; 42(1): 230-8.
40. **Richeldi L**. Idiopathic pulmonary fibrosis: current challenges and future perspectives. *Eur Respir Rev.* 2013; 22(128): 103-5.
41. Costabel U, Albera C, Behr J, Cottin V, Guenther A, **Richeldi L**. Idiopathic pulmonary fibrosis in 2011: key updates on guidelines and therapeutics. *Respir Res.* 2013; 14 Suppl 1: S1.
42. **Richeldi L**. Clinical trials of investigational agents for IPF: a review of a Cochrane report. *Respir Res.* 2013; 14 Suppl 1: S4.
43. Behr J, **Richeldi L**. Recommendations on treatment for IPF. *Respir Res.* 2013; 14 Suppl 1: S6.
44. Jones MG, Fletcher S, **Richeldi L**. Idiopathic pulmonary fibrosis: recent trials and current drug therapy. *Respiration.* 2013; 86(5): 353-63.
45. Cottin V, **Richeldi L**. Neglected evidence in idiopathic pulmonary fibrosis and the importance of early diagnosis and treatment. *Eur Respir Rev.* 2014; 23: 106-10.
46. Jones MG, **Richeldi L**. Air pollution and acute exacerbations of idiopathic pulmonary fibrosis: back to miasma? *Eur Respir J.* 2014; 43: 956-9.
47. Fischer A, **Richeldi L**. Cross-disciplinary collaboration in connective tissue disease-related lung disease. *Semin Respir Crit Care Med.* 2014; 35(2): 159-65.
48. Cottin V, **Richeldi L**. Neglected evidence in idiopathic pulmonary fibrosis and the importance of early diagnosis and treatment. *Eur Respir Rev.* 2014; 23: 106-10.
49. Jones MG, **Richeldi L**. Air pollution and acute exacerbations of idiopathic pulmonary fibrosis: back to miasma? *Eur Respir J.* 2014; 43: 956-9.
50. Ryerson CJ, Corte TJ, Collard HR, **Richeldi L**. A global registry for idiopathic pulmonary fibrosis: the time is now. *Eur Respir J.* 2014; 44: 273-6.

51. Wuyts WA, Antoniou KM, Borensztajn K, Costabel U, Cottin V, Crestani B, Grutters JC, Maher TM, Poletti V, **Richeldi L**, Vancheri C, Wells AU. Combination therapy: the future of management for idiopathic pulmonary fibrosis? *Lancet Respir Med*. 2014; 2: 933-42.
52. Moodley Y, Corte T, **Richeldi L**, King TE Jr. Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective. *Respirology* 2015; 20(3): 389-94.
53. Spagnolo P, Maher TM, **Richeldi L**. Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy. *Pharmacol Ther*. 2015; 152: 18-27.
54. Collard HR, Bradford WZ, Cottin V, Flaherty KR, King TE Jr, Koch GG, Kolb M, Martinez FJ, Montgomery B, Raghu G, **Richeldi L**, Rose D, Wells AU, Brown KK. A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials. *Eur Respir J*. 2015; 46: 243-9.
55. **Richeldi L**. Efficacy endpoints for idiopathic pulmonary fibrosis trials. *Lancet Respir Med*. 2015; 3: 335-7.
56. Mazzei ME, **Richeldi L**, Collard HR. Nintedanib in the treatment of idiopathic pulmonary fibrosis. *Ther Adv Respir Dis*. 2015; 9: 121-129.
57. **Richeldi L**, Rubin AS, Avdeev S, Udwadia ZF, Xu ZJ. Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China. *BMC Med*. 2015 Sep 24;13(1):237. doi: 10.1186/s12916-015-0495-0.
58. **Richeldi L**. Idiopathic pulmonary fibrosis: moving forward. *BMC Med*. 2015 Sep 24;13(1):231. doi: 10.1186/s12916-015-0481-6.
59. **Richeldi L**. Time for Prevention of Idiopathic Pulmonary Fibrosis Exacerbation. *Ann Am Thorac Soc*. 2015; 12 Suppl 2: S181-5.
60. Sgalla G, Biffi A, **Richeldi L**. Idiopathic pulmonary fibrosis: Diagnosis, epidemiology and natural history. *Respirology* 2016; 21: 427-37.
61. Britten N, Pope C, Halford S, **Richeldi L**. What if we made stratified medicine work for patients? *Lancet Respir Med*. 2016; 4: 8-10.
62. Sgalla G, Cocconcelli E, Tonelli R, **Richeldi L**. Novel drug targets for idiopathic pulmonary fibrosis. *Expert Rev Respir Med*. 2016: 1-13.
63. Jones MG, Walsh SL, Jones KD, **Richeldi L**. Idiopathic pulmonary fibrosis: securing a confident diagnosis for every patient. *Eur Respir J*. 2016; 47: 1057-9.
64. Brownell R, Kaminski N, Woodruff PG, Bradford WZ, **Richeldi L**, Martinez FJ, Collard HR. Precision Medicine: The New Frontier in Idiopathic Pulmonary Fibrosis. *Am J Respir Crit Care Med*. 2016; 193: 1213-8.
65. Kolb M, Jenkins G, **Richeldi L**. Study the past to divine the future. Confucius' wisdom doesn't work for idiopathic pulmonary fibrosis. *Thorax*. 2016; 71: 399-400.
66. **Richeldi L**. How we will diagnose IPF in the future. *QJM*. 2016; 109: 581-3.
67. Fletcher S, Jones MG, Spinks K, Sgalla G, Marshall BG, Limbrey R, **Richeldi L**. The safety of new drug treatments for idiopathic pulmonary fibrosis. *Expert Opin Drug Saf*. 2016; 15: 1483-1489.
68. Martinez FJ, Chisholm A, Collard HR, Flaherty KR, Myers J, Raghu G, Walsh SL, White ES, **Richeldi L**. The diagnosis of idiopathic pulmonary fibrosis: current and future approaches. *Lancet Respir Med*. 2017; 5: 61-71.

CASE REPORTS

1. **Richeldi L**, Rossi G, Ruggieri MP, Corbetta L, Fabbri LM. Churg-Strauss syndrome in a case of asthma. *Allergy*. 2002; 57(7): 647-8.
2. Rossi G, Cavazza A, Valli R, Torricelli P, **Richeldi L**, Rivasi F, Brambilla E. Atypical lipomatous tumour (lipoma-like well-differentiated liposarcoma) arising in a pulmonary hamartoma and clinically presenting with pneumothorax. *Lung Cancer*. 2003; 39(1): 103-6.
3. Andreani A, Cavazza A, Marchioni A, **Richeldi L**, Paci M, Rossi G. Bronchopulmonary actinomycosis associated with hiatal hernia. *Mayo Clin Proc*. 2009; 84(2): 123-8.
4. Canali E, Sola P, **Richeldi L**, Spagnolo P, Mora G, Georgouloupoulou E, Bernabei C, Malaguti MC, Valzania F, Mandrioli J. Amyotrophic lateral sclerosis and sarcoidosis: a difficult differential diagnosis. *Amyotroph Lateral Scler*. 2010; 11(4): 410-1.

5. Garlassi E, Rossi G, Bedini A, **Richeldi L**. Unexpected identification of bilateral masses in an asymptomatic heavy smoker. *Thorax*. 2010; 65(9): 846.
6. Contini P, Schiavina M, Schiavina R, Tavalazzi F, Fabiani A, Di Scioscio V, Spagnolo P, **Richeldi L**. Efficacy of hormonal suppression in a patient with chyluria due to lymphangiomyomatosis. *Multidiscip Respir Med*. 2011; 6(5): 313-7.
7. Bargellini A, Marchesi I, Marchegiano P, **Richeldi L**, Cagarelli R, Ferranti G, Borella P. A culture-proven case of community-acquired legionella pneumonia apparently classified as nosocomial: diagnostic and public health implications. *Case Rep Med*. 2013; 2013: 303712.
8. Cerri S, Sgalla G, **Richeldi L**, Luppi F. Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: a case report. *J Med Case Rep*. 2016; 10: 127.

LETTERS

1. **Richeldi L**. Interferon gamma-1b for pulmonary fibrosis. *N Engl J Med*. 2004; 350(17): 1794-7; author reply -7.
2. Lalvani A, **Richeldi L**, Kunst H. Interferon gamma assays for tuberculosis. *Lancet Infect Dis*. 2005; 5(6): 322-4; author reply 5-7.
3. Spagnolo P, Luppi F, Rossi G, **Richeldi L**. To BAL or not to BAL: is this a problem in diagnosing IPF? *Am J Respir Crit Care Med*. 2009; 180(4): 379-80; author reply 80.
4. Ferrara G, Parida SK, Zumla A, **Richeldi L**, Maeurer M. A decade of interferon-gamma release assays: quest for the holy grail to diagnose latent infection with mycobacterium tuberculosis? *Am J Respir Crit Care Med*. 2011; 183(12): 1732.
5. Spagnolo P, Luppi F, **Richeldi L**. The reply. *Am J Med*. 2013; 126(1): e19.
6. **Richeldi L**. Treatments for idiopathic pulmonary fibrosis. *N Engl J Med*. 2014; 371: 783.
7. **Richeldi L**, Le Maulf F, Schlenker-Herceg R, Collard HR. Reply: Weight-Loss Effect on FVC in Nintedanib Idiopathic Pulmonary Fibrosis Trials? *Am J Respir Crit Care Med*. 2015; 192: 1020-1.

LIBRI E MONOGRAFIE (editoriali)

1. Interstitial Lung Diseases. Du Bois RM, **Richeldi L** editors. *Eur Respir Mon*. 2009, issue 46.
2. Orphan lung diseases: a clinical guide to rare lung disease. Cottin V, Cordier JF and **Richeldi L** editors, Springer Verlag 2015, in press. ISBN: 978-1-4471-2400-9.
3. Orphan Lung Diseases for *Seminars in Respiratory and Critical Care Medicine* 2016: 37: #2 (Jay Ryu and Luca Richeldi, Guest Editors)

LIBRI E MONOGRAFIE (capitoli)

1. Saltini C, **Richeldi L**, Holroyd KJ, du Bois RM, Crystal RG. Lymphocytes. The Lung: Scientific Foundations. Crystal RG and West JB editors. Raven Press, New York, N.Y. 1991, 459-82.
2. Saltini C, **Richeldi L**. A genetic marker for chronic beryllium disease. Workshop on the practical applications of biomarkers in medicine. The development and applications of biomarkers Ed. DOE-EH-0377T. U.S. Department of Energy, Washington D.C., April 15, 1994, 51.
3. **Richeldi L**, Franchi A, Rovatti E, Cossarizza A, du Bois RM, Saltini C. Lymphocytes. The Lung: Scientific Foundations. 2nd edition. Crystal RG, West JB, Weibel ER, Barnes PJ editors. Raven Press, New York, N.Y. 1997, 187-99.
4. Rovatti E, Franchi A, **Richeldi L**, Saltini C. Lymphokines and the lung. The Lung: Scientific Foundations. 2nd edition. Crystal RG, West JB, Weibel ER, Barnes PJ editors. Raven Press, New York, N.Y. 1997, 803-20.
5. Robinson DS, **Richeldi L**, Saltini C, du Bois RM. Granulomatous processes. The Lung: Scientific Foundations. 2nd edition. Crystal RG, West JB, Weibel ER, Barnes PJ editors. Raven Press, New York, N.Y. 1997, 2395-409.
6. Saltini C, **Richeldi L**, Amicosante M. HLA and respiratory disease. HLA in health and disease. Lechler R and Warrens A editors. Academic Press, London 2000, 263-77.

7. Romagnoli M, **Richeldi L**, Fabbri LM. Diagnosis. Asthma and COPD. Basic mechanisms and clinical management. Barnes PJ, Drazen JM, Rennard S, Thomason NC editors. Academic Press, London 2002, 447-55.
8. Fabbri LM, Romagnoli M, **Richeldi L**, Olivieri D. Asthma versus chronic obstructive pulmonary disease. *Eur Respir Mon.* 2003; 23: 195-210.
9. Selman M, Spagnolo P, **Richeldi L**. Interstitial lung disease in elderly subjects. *Eur Respir Mon.* 2009; 43: 150-62.
10. Spagnolo P, **Richeldi L**, Raghu G. The role of bronchoalveolar lavage cellular analysis in the diagnosis of interstitial lung diseases. *Eur Respir Mon.* 2009; 46: 36-46.
11. Cerri S, Spagnolo P, Luppi F, **Richeldi L**. Smoking-related interstitial lung disease. *Eur Respir Mon.* 2011; 54: 282-300.
12. King TE, Jr., Collard HR, **Richeldi L**. Interstitial lung diseases. Preface. *Clin Chest Med.* 2012; 33(1): xiii.
13. Cerri S, Spagnolo P, Luppi F, **Richeldi L**. Management of idiopathic pulmonary fibrosis. *Clin Chest Med.* 2012; 33: 85-94.
14. Spagnolo P, Luppi F, Montanari G, **Richeldi L**. Pharmacological Treatment of Idiopathic Pulmonary Fibrosis. Idiopathic Pulmonary Fibrosis: A Comprehensive Clinical Guide. Meyer KC and Nathan S editors. Springer 2014, volume 9, pages 297-311. ISBN: 978-1-62703-681-8.

Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali"

Prof. Luca Richeldi

1 marzo 2018